Now that AstraZeneca’s oral PCSK9 inhibitor AZD0780 has successfully navigated a Phase IIb trial, attention can now shift to baxdrostat, a second cardiovascular candidate the UK firm believes can have peak sales of over $5bn.
Key Takeaways
- Readouts from two Phase III trials of the aldosterone synthase inhibitor are expected in the second half of 2025
In a recent interview with Scrip, Mikhail Kosiborod, head of late-stage development for AstraZeneca’s cardiovascular, renal and metabolic (CVRM) diseases franchise, said that among the readouts the company has planned up to the end of 2025, “the one I’d probably highlight is baxdrostat.” The novel aldosterone synthase inhibitor (ASI), which AstraZeneca got hold of through its